The report of Deloitte's rapid review reads more like a case to reverse the defunding decision and for the removal of the officials responsible for the administration of federally-funded quality use programs. …
Did anyone actually read this report before confirming the decision?
September 16, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Argenica validates optimal dose of ARG-007 in independent preclinical stroke study
November 25, 2025 - - Australian Biotech -
NSW Premier opens Australia’s first large-scale health translation hub at UNSW
November 24, 2025 - - Latest News -
Cynata completes final patient visits in pivotal Phase 3 osteoarthritis trial
November 24, 2025 - - Australian Biotech -
New review recommends a balanced and measured approach to adopting AI in clinical practice
November 24, 2025 - - BioPharma -
Sanofi becomes first tenant of ENTRI, marking major step for Queensland’s translational research ambitions
November 24, 2025 - - Latest News -
Moderna names CSIRO scientist Dr Anne Klein as 2025 Australian Fellow
November 24, 2025 - - Australian Biotech -
New national report warns of deepening ovarian cancer burden and calls for urgent action
November 24, 2025 - - Latest News